Takeda Pharmaceutical Company Limited (TAK) Insider Trading Activity

NYSE$21.055+0.3 (1.45%)
Market Cap
$66.29B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
794 of 849
Rank in Industry
44 of 48

TAK Insider Trading Activity

TAK Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$13,204,422
19
100

Related Transactions

Ibrahim Ramy Riad AhmedPresident, PDT BU
0
$0
1
$124,437
$-124,437
Farajallah Awny Samaan BotrosChief Medical Officer
0
$0
1
$239,503
$-239,503
Pacheco Rhonda JanicePresident, U.S. Business Unit
0
$0
1
$289,007
$-289,007
Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev
0
$0
1
$392,565
$-392,565
Shannon Elaine MaryPres., Global Supply & Quality
0
$0
2
$425,394
$-425,394
Ricci GabrieleChief Data & Tech. Officer
0
$0
1
$429,005
$-429,005
Furney Natalie Anne MarieGlobal General Counsel
0
$0
1
$527,843
$-527,843
Platford Giles RichardPresident, IBU
0
$0
1
$531,519
$-531,519
Bitetti Teresa MariePresident, OBU
0
$0
1
$855,205
$-855,205
Greenway Nicola Deidre PetalChief Human Resources Officer
0
$0
3
$1.07M
$-1.07M
Duprey Lauren RusckowskiChief Transformation Officer
0
$0
2
$1.45M
$-1.45M
Kim Julie So-YoungPresident and CEO
0
$0
1
$1.52M
$-1.52M
Plump Andrew StewartPresident, R&D
0
$0
3
$5.34M
$-5.34M

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, …

Insider Activity of Takeda Pharmaceutical Company Limited

Over the last 12 months, insiders at Takeda Pharmaceutical Company Limited have bought $0 and sold $13.2M worth of Takeda Pharmaceutical Company Limited stock.

On average, over the past 5 years, insiders at Takeda Pharmaceutical Company Limited have bought $0 and sold $13.2M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

List of Insider Buy and Sell Transactions, Takeda Pharmaceutical Company Limited

2026-09-14SaleDuprey Lauren RusckowskiChief Transformation Officer
34,535
0.0011%
$18.54
$640,279
+1.64%
2026-09-02SalePlump Andrew StewartPresident, R&D
116,191
0.0037%
$18.49
$2.15M
+2.06%
2026-08-19SalePlump Andrew StewartPresident, R&D
19,651
0.0006%
$18.49
$363,347
+1.64%
2026-08-18SaleGreenway Nicola Deidre PetalChief Human Resources Officer
12,980
0.0004%
$18.11
$235,118
+3.16%
2026-08-11SaleShannon Elaine MaryPres., Global Supply & Quality
20,363
0.0006%
$17.55
$357,371
+5.95%
2026-08-10SalePlump Andrew StewartPresident, R&D
165,393
0.0051%
$17.10
$2.83M
+5.53%
2026-08-10SaleKim Julie So-YoungPresident and CEO
89,090
0.0027%
$17.10
$1.52M
+5.53%
2026-08-10SalePlatford Giles RichardPresident, IBU
31,083
0.001%
$17.10
$531,519
+5.53%
2026-08-10SaleBitetti Teresa MariePresident, OBU
50,012
0.0015%
$17.10
$855,205
+5.53%
2026-08-10SaleDuprey Lauren RusckowskiChief Transformation Officer
47,586
0.0015%
$17.10
$813,721
+5.53%
2026-08-10SaleFurney Natalie Anne MarieGlobal General Counsel
30,868
0.001%
$17.10
$527,843
+5.53%
2026-08-10SalePacheco Rhonda JanicePresident, U.S. Business Unit
16,901
0.0005%
$17.10
$289,007
+5.53%
2026-08-10SalePignagnoli Agosti MarcelloHead, Strat. & Port. Dev
22,957
0.0007%
$17.10
$392,565
+5.53%
2026-08-10SaleRicci GabrieleChief Data & Tech. Officer
25,088
0.0008%
$17.10
$429,005
+5.53%
2026-08-10SaleFarajallah Awny Samaan BotrosChief Medical Officer
14,006
0.0004%
$17.10
$239,503
+5.53%
2026-08-10SaleIbrahim Ramy Riad AhmedPresident, PDT BU
7,277
0.0002%
$17.10
$124,437
+5.53%
2026-08-10SaleShannon Elaine MaryPres., Global Supply & Quality
3,978
0.0001%
$17.10
$68,024
+5.53%
2026-08-10SaleGreenway Nicola Deidre PetalChief Human Resources Officer
41,377
0.0013%
$17.44
$721,613
+5.53%
2026-08-10SaleGreenway Nicola Deidre PetalChief Human Resources Officer
6,774
0.0002%
$17.10
$115,835
+5.53%
Total: 19
*Gray background shows transactions not older than one year

TAK Institutional Investors: Active Positions

Increased Positions172+42.16%13M+14.06%
Decreased Positions176-43.14%21M-22.5%
New Positions68New1MNew
Sold Out Positions46Sold Out8MSold Out
Total Postitions404-0.98%84M-8.45%

TAK Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.